PRIMENENIE TOTsILIZUMABA U DETEY S POLIARTIKULYaRNYM VARIANTOM YuVENIL'NOGO IDIOPATIChESKOGO ARTRITA, REZISTENTNOGO K TERAPII METOTREKSATOM


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The results of the study to evaluate the efficacy and safety of tocilizumab (TCZ) in children with polyarticular juvenile idiopathic arthritis option (pYulA) resistant to previous therapy with conventional disease modifying anti-rheumatic drugs (DMARDs), treated with tocilizumab (TCZ) at a dose of 8 mg/kg every 4 weeks for 6-42 months. The study shows the long-term efficacy and safety of TCZ in patients with polyarticular JIA option, high-status «inactive disease», TCZ monotherapy indistinguishable from combination therapy with methotrexate TCZ. There were no differences in the effectiveness of the treatment of patients with previously untreated and treated GIBP During therapy with TCZ no serious adverse events that led to the abolition of therapy.

Full Text

Restricted Access

References

  1. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767-78.
  2. Cassidy J., Petty R., Laxer R.M., Lindsley C.B. Textbook of Pediatric Rheumatology. 6th ed. Elsevier. 2011. 794 p.
  3. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A.M., Suarez-Almazor M.E., Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J. Rheumatol. 2004;31:390-92.
  4. Hashkes P.J., Laxer R.M. Medical treatment of juvenile idiopathic arthritis, JAMA. 2005;294( 13): 1671-84.
  5. Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., DeWitt E.M., Ilowite N.T., Kimura Y., Laxer R.M., Lovell D.J., Martini A., Rabinovich C.E., Ruperto N. 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care & Research. 2011;63(4):465-82.
  6. Grom A.A., Murray K.J., Luyrink L., Emery H., Passo M.H., Glass D.N., Bowlin T., Edwards C. 3rd. Patterns of expression of tumor necrosis factor a, tumor necrosis factor b, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum. 1996; 39:1703-10.
  7. De Benedetti F., Robbioni P., Massa M., Viola S., Albani S., Martini A. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin. Exp. Rheumatol. 1992;10:493-98.
  8. Fleischmann R.M., Tesser J., Schiff M.H., Schechtman J., Burmester G-R., Bennett R., Modafferi D., Zhou L., Bell D., Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006;65:1006-12.
  9. Nigrovic P.A., Mannion M., Prince F.H., Zeft A., Rabinovich C.E., van Rossum M.A., Cortis E., Pardeo M., Miettunen P.M., Janow G., Birmingham J., Eggebeen A., Janssen E., Shulman A.I., Son M.B., Hong S., Jones K., Ilowite N.T., Cron R.Q., Higgins G.C. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-55.
  10. DeWitt E.M., Kimura Y., Beukelman T., Nigrovic P.A., Onel K., Prahalad S., Schneider R., Stoll M.L., Angeles-Han S., Milojevic D., Schikler K.N., Vehe R.K., Weiss J.E., Weiss P., Ilowite N.T., Wallace C.A. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken). 2012;64(7):1001-10.
  11. Vastert S.J., de Jager W., Noordman B.J., Holzinger D., Kuis W., Prakken B.J., Wulffraat N.M. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034-43.
  12. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., Brik R., McCann L., Kasapcopur O., Rutkowska-Sak L., Schneider R., Berkun Y., Calvo I., Erguven M., Goffin L., Hofer M., Kallinich T., Oliveira S.K., Uziel Y., Viola S., Nistala K., Wouters C., Cimaz R., Ferrandiz M.A., Flato B., Gamir M.L., Kone-Paut I., Grom A., Magnusson B., Ozen S., Sztajnbok F., Lheritier K., Abrams K., Kim D., Martini A., Lovell D.J. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012;367(25):2396-406.
  13. Ringold S., Weiss P.F., Beukelman T., DeWitt E.M., Ilowite N.T, Kimura Y., Laxer R.M., Lovell D.J., Nigrovic P.A., Robinson A.B., Vehe R.K. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013;65(10):2499-512.
  14. Kimura Y., Morgan Dewitt E., Beukelman T., Nigrovic P.A., Onel K., Prahalad S., Schneider R., Stoll M.L.; Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;Apr 9. doi: 10.1002/ acr.22343. [Epub ahead of print]
  15. Ilowite N.T., Prather K., Lokhnygina Y., Schanberg L.E., Elder M., Milojevic D., Verbsky J.W., Spalding S.J., Kimura Y., Imundo L.F., Punaro M.G., Sherry D.D., Tarvin S.E., Zemel L.S., Birmingham J.D., Gottlieb B.S., Miller M.L., O'Neil K., Ruth N.M., Wallace C.A., Singer N.G., Sandborg C.I. The randomized placebo phase study of rilonacept in the treatment of systemic juvenile idiopathic arthritis (RAPPORT). Arthritis Rheumatol. 2014;May 16. doi: 10.1002/art.38699. [Epub ahead of print].
  16. Ilowite N., Porras O., Reiff A., Rudge S., Punaro M., Martin A, Allen R., Harville T., Sun Y.N., Bevirt T., Aras G., Appleton B. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin. Rheumatol. 2009;28(2):129-37.
  17. Brunner H.I., Ruperto N., Zuber Z., Keane C., Harari O., Kenwright A., Lu P., Cuttica R., Keltsev V., Xavier R.M., Calvo I., Nikishina I., Rubio-Perez N., Alexeeva E., Chasnyk V., Horneff G., Opoka-Winiarska V., Quartier P., Silva C.A., Silverman E., Spindler A., Baildam E., Gamir M.L., Martin A., Rietschel C., Siri D., Smolewska E., Lovell D., Martini A., De Benedetti F. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2014;May 16. pii: annrheumdis -2014-205351. doi: 10.1136/annrheumdis -2014-205351. [Epub ahead of print].
  18. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishimoto N., Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371 (961 7):998-1006.
  19. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., Cuttica R., Ravelli A., Schneider R., Woo P., Wouters C., XavierR.,Zemel L.,Baildam E.,Burgos-Vargas R., Dolezalova P., Garay S.M., Merino R., Joos R., Grom A., Wulffraat N., Zuber Z., Zulian F., Lovell D., Martini A. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012;367(25): 2385-95.
  20. Imagawa T., Yokota S., Mori M., Miyamae T., Takei S., Imanaka H., Nerome Y., Iwata N., Murata T., Miyoshi M., Nishimoto N., Kishimoto T. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod. Rheumatol. 2012;22:109-115.
  21. Wallace C.A., Ruperto N., Giannini E.H. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004;31:2290-94.
  22. Isaacs J.D., Harari O., Kobold U., Lee J.S., Bernasconi C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res. Ther. 2013;15(6):R204.
  23. Ringold S., Tzaribachev N., Cron R.Q. Management of temporomandibular joint arthritis in adult rheumatology practices: a survey of adult rheumatologists. Pediatr. Rheumatol. Online J. 2012;10(1):26.
  24. Костик М.М., Дубко М.Ф., Снегирёва Л.С., Масалова В.В., Корнишина Т.Л., Лихачёва Т.С., Чикова И.А., Исупова Е.А., Кучинская Е.М., Глебова Н.И., Калашникова О.В., Часнык В.Г. Сравнительная характеристика разных режимов терапии тоцилизумабом у пациентов с системным ювенильным идиопатическим артритом. Вопросы современной педиатрии. 2013; 12(5):18-23.
  25. Otten M.H., Prince F.H., Anink J., Ten Cate R., Hoppenreijs E.P., Armbrust W., Koopman-Keemink Y., van Pelt P.A., Kamphuis S., Gorter S.L., Dolman K.M., Swart J.F., van den Berg J.M., Wulffraat N.M., van Rossum M.A., van Suijlekom-Smit L.W. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann. Rheum. Dis. 2013;72(5): 721-27.
  26. Giannini E.H., Ilowite N.T., Lovell D.J., Wallace C.A., Rabinovich C.E., Reiff A., Higgins G., Gottlieb B., Singer N.G., Chon Y., Lin S-L., Baumgartner S.W. Long-Term Safety and Effectiveness of Etanercept in Children With Selected Categories of Juvenile Idiopathic Arthritis. Arthr. Rheum. 2009;60(9): 2794-804.
  27. Lovell D.J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., Nemcova D., Mouy R., Sandborg C., Bohnsack J., Elewaut D., Foeldvari I., Gerloni V., Rovensky J., Minden K., Vehe R.K., Weiner L.W., Horneff G., Huppertz H.I., Olson N.Y., Medich J.R., Carcereri-De-Prati R., McIlraith M.J., Giannini E.H., Martini A.; Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008;359(8):810-20.
  28. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 2010;69:88-96.
  29. Dougados M., Kissel K., Sheeran T., Tak P.P., Conaghan P.G., Mola E.M., Schett G., Amital H., Navarro-Sarabia F., Hou A., Bernasconi C., Huizinga T. W.J. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 2013;72:43-50.
  30. Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K., Klearman M., Musselman D., Agarwal S., Green J., Kavanaugh A. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phasetrial. Lancet. 2013;381(9877):1541-50.
  31. Meyer S., Haist M.,Schaefer S., Ivan D., Ittner J.R., Nawroth P.P., Plöckinger U., Stalla G.K., Tuschy U., Weber M.M., Weise A., Pfützner A., Habbe N., Kann P.H. Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics. 2008;9(8):101-26.
  32. Benedetti F.D., Rubio-Perez N., Salazar C.D., Goodman S., Job-Deslandre C., Joos R., Kone-Paut I., Minden K., Onel K., Porter-Brown B., Bharucha K., Wang J., Martini A., Lovell D.J., Brunner H.I. A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis. Arthr. Rheumatol. 2014;66(Suppl. 11):S67-8.
  33. De Benedetti F., Ruperto N., Baildam E., Burgos-Vargas R., Horneff G., Huppertz H.I., Minden K., Myones B.L., Onel K., Wang J., Bharucha K.N., Lovell D.J., Martini A., Brunner H. A14: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis. Arthr. Rheumatol. 2014;66(Suppl. 11):S23-4.
  34. Navarro-Millan I., Singh J.A., Curtis J.R. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin. Ther. 2012;34:788-802.e3.
  35. Schiff M.H., Kremer J.M., Jahreis A., Vernon E., I saacs J.D., van Vollenhoven R.F. Integrated safety in tocilizumab clinical trials. Arthr. Res. Ther. 2011;13(5):R141.
  36. Yokota S., Imagawa T., Mori M., Miyamae T., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishimoto N., Kishimoto T. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J. Rheumatol. 2014;41(4):759-67.
  37. Basic J., Pavlovic D., Jevtovic-Stoimenov T., Vojinovic J., Susic G., Stojanovic I., Kocic G., Milosevic V., Cvetkovic T., Marinkovic M., Veljkovic A. Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype. J. Physiol. Biochem. 2010;66(2):173-80.
  38. Lee Y.H., Bae S.C., Song G.G. Functional gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics. 2006;7(5):683-95.
  39. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Perez N., Silva C.A., Abud-Mendoza C., Burgos-Vargas R., Gerloni V., Melo-Gomes J.A., Saad-Magalhaes C., Sztajnbok F., Goldenstein-Schainberg C., Scheinberg M., Penades I.C., Fischbach M., Orozco J., Hashkes P.J., Hom C., Jung L., Lepore L., Oliveira S., Wallace C.A., Sigal L.H., Block A.J., Covucci A., Martini A., Giannini E.H.; Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383-91. FCGR3A 158 V/F and lL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. Rheumatol. int. 2014;Apr 12. [Epub ahead of print]
  40. Tolusso B., Pietrapertosa D., Morelli A., De Santis M., Gremese E., Farina G., Carniello S.G., Del Frate M., Ferraccioli G. IL-1B and IL-1RN

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies